+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Traditional Chinese Medicine Is Widely Used for Cardiovascular Disease

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          A review article by Hao et al. ( J Am Coll Cardiol 2017;69(24):2952–66) has had huge repercussions among those familiar with traditional Chinese medicine (TCM) in the international academic community. It evaluated the efficacy and safety of TCM for cardiovascular disease and the pharmacological effect of active TCM ingredients on the cardiovascular system and potential mechanisms. We have several comments: Firstly, we give a brief summary addressing nonpharmacotherapy in TCM, including acupuncture, moxibustion, Qigong, and Tai Chi. Secondly, we have added traditional antiarrhythmic drug–related randomized controlled trials to make the coverage more comprehensive. Lastly, we support the concept that research into, development of, and application of active ingredients is part of modern TCM.

          Related collections

          Most cited references 22

          • Record: found
          • Abstract: not found
          • Article: not found

          Acupuncture for chronic severe functional constipation: a randomized trial

           Z LIU,  S YAN,  J Wu (2016)
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial.

            Acupuncture is used to induce ovulation in some women with polycystic ovary syndrome, without supporting clinical evidence.
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial

              Background: Premature ventricular contractions (PVCs) are common in the general population, and frequent PVCs may result in the poor quality of life or even the damage of cardiac function. We examined the efficacy and safety of a traditional Chinese medicine Wenxin Keli for the treatment of frequent PVCs among a relatively large Chinese cohort. Methods: We performed a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. A total of 1200 eligible participants were randomly assigned in a ratio of 1:1 to receive Wenxin Keli or the placebo for 4 weeks. The primary and secondary endpoint was the change of PVC numbers and PVC-related symptoms after a 4-week treatment compared with baseline, respectively. In addition, vital signs, laboratory values, and electrocardiographic parameters were assessed in a safety analysis. Results: At the initial evaluation, no significant differences in the baseline characteristics were observed between the Wenxin Keli group and the placebo group. A smaller number of PVCs was observed after the 4-week treatment than at baseline, in both the Wenxin Keli group (5686 ± 5940 vs. 15,138 ± 7597 beats/d, P < 0.001) and the placebo group (10,592 ± 8009 vs. 14,529 ± 5929 beats/d, P < 0.001); moreover, the Wenxin Keli group demonstrated a significantli greater reduction in the frequency of PVCs than the placebo group (P < 0.001). In a full analysis set, patients in the Wenxin Keli group exhibited significantly higher total effective responses in the reduction of PVCs compared to those in the placebo group (83.8% vs. 43.5%, P < 0.001). The per-protocol analysis yielded similar results (83.0% vs. 39.3%, P < 0.001). Treatment with Wenxin Keli also demonstrated superior performance compared to the placebo with respect to PVC-related symptoms. No severe adverse effects attributable to Wenxin Keli were reported. Conclusions: Wenxin Keli treatment effectively reduced the overall number of PVCs and alleviated PVC-related symptoms in patients without structural heart diseases and had no severe side effects.

                Author and article information

                Cardiovascular Innovations and Applications
                Compuscript (Ireland )
                May 2018
                May 2018
                : 3
                : 1
                : 123-126
                1Guang’ Anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100053, China
                2Global Genetics Corporation, Ventura, CA 93003, USA
                3Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, Wuhan 430060, China
                4Hubei Key Laboratory of Cardiology, Wuhan 430060, China
                Author notes
                Correspondence: Dan Hu, MD, PhD, Professor, FAHA, FACC, FHRS, FAPHRS, Department of Cardiology and Cardiovascular Research Institute, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China, Tel.: +86-27-88041911, Fax: +86-27-88042293, E-mail: hudan0716@
                Copyright © 2018 Cardiovascular Innovations and Applications

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See

                Letter to the Editor


                Comment on this article